NPC1L1 and coronary artery disorder: The analysis conducted through the IVW method indicates that statins (OR [95%confidence interval (CI)] = 0.73 [0.67, 0.80)], p = 3.98 × 10–11), PCSK9 inhibitors (OR [95%CI] = 0.65 [0.57, 0.73], p = 6.44 × 10–12), and NPC1L1 inhibitors (OR [95%CI] = 0.58 [0.43, 0.78], p = 0.0003) significantly reduce the risk of CHD (Table 1 and Figure 2).